Table 1.
Model | Key Features | Rupture Characteristics | Reference |
---|---|---|---|
Genetic | |||
Timp-1 -/- Deficient in TIMP-1 gene |
Proteolysis ECM degradation Inflammation Aneurysms in both the thoracic and abdominal regions of the aorta |
No ruptures reported | [34,35,36,37,38,39] |
ApoE -/- Deficient in ApoE gene |
Dyslipidemia Atherosclerosis Require other AAA induction agents such as high fat diet or chemical induction |
No ruptures reported in genetic deficiency alone | [40,41,42,43,44,45] |
Blotchy and Lox -/- | Lack crosslinks between elastin and collagen fibers Elastin fragmentation VSMC apoptosis Aneurysms along the full length of the aorta |
No ruptures reported in most studies One study reports that males do rupture and females do after hydrocortisone treatment |
[46,47,48,49] [31] |
Overexpression of Renin and Angiotensinogen | Hypertension, Inflammation Medial degeneration Require high salt intake Aneurysms and ruptures Aneurysms in the thoracic and abdominal regions of the aorta |
No ruptures reported | [50,51] |
Chemical | |||
CaCl2 Painting solubilised CaCl2 on the exposed IRA |
Aortic calcification Medial degeneration Inflammatory cells infiltration |
No ruptures reported | [32,52,53,54] |
CaPO4 Painting solubilised CaPO4 on the exposed IRA |
Aortic calcification Medial degeneration Inflammatory cells infiltration |
No ruptures reported | [55,56] |
AngII infusion Delivering AngII through subcutaneously implanted osmotic pumps |
Acute aortic dissections, aneurysms and ruptures Upregulation of chemokines and pro-inflammatory cytokines Leukocyte infiltration ECM degeneration VSMC apoptosis |
Ruptures often occur within first week of AngII infusion in the arch, thoracic and SRA regions | [33,57,58,59,60] |
AngII + BAPN AngII infusion to mice that had received BAPN |
Leads to higher incidence of AAA Medial ECM degeneration VSMC apoptosis Dissections are common with presence of ILT and IMT |
Fatal medial ruptures in the IRA | [61,62,63,64] |
AngII + Leptin Peri-aortic application of Leptin in the ApoE-/- mouse combined with AngII infusion |
ECM degeneration MMP up-regulation Macrophage infiltration Dissections and IMT are present |
No ruptures reported | [65] |
AngII + anti-TGF-β antibody | Aortic dissection Enhanced monocyte infiltration Increased MMP-12 activity |
Increased rupture in both the ascending aorta and SRA | [66,67] |
Elastase perfusion Elastase is delivered through a catheter placed in the IRA |
Inflammation Medial degeneration and ILT present |
No ruptures reported | [68,69,70,71] |
Elastase + TGF-β activity Blocking Combined adventitial application of Elastase and neutralizing TGF-β activity by mouse monoclonal antibody |
Enhanced elastin degradation Ongoing inflammation Presence of large amount of ILT |
Fatal rupture in IRA | [72,73] |
Elastase + BAPN Combined adventitial application of Elastase on mice that had received BAPN |
Higher AAA incidence Medial ECM degeneration VSMC apoptosis ILT presence |
Fatal rupture in IRA | [62,74] |
Abbreviations: AngII, angiotensin II; ApoE, apolipoprotein E; BAPN, β-aminopropionitrile monofumarate; CaCl2, calcium chloride, CaPO4, calcium phosphate; ECM, extracellular matrix; ILT, intra-luminal thrombus; IMT, intra-mural thrombus; IRA, infrarenal aorta; Lox, lysyl oxidase; MMP, matrix metalloproteinase; SRA, suprarenal aorta; TIMP, tissue inhibitor of metalloproteinase; VSMC, vascular smooth muscle cells.